A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) (NCT04624659)
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Who can join: Review the eligibility criteria below.
Location: Univ of Alabama Birmingham — Birmingham, Alabama
Age range: 12 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (142 Sites)
Showing the first 25 of 142 sites.
- Univ of Alabama Birmingham — Birmingham, Alabama
- Phoenix Children's Hsptl — Phoenix, Arizona
- [Legal] Woodland International Research Group, LLC — Little Rock, Arkansas
- [Legal] Collaborative Neuroscience Network, LLC — Long Beach, California
- Pacific Research Partners — Oakland, California
- UCSF Oakland Benioff ChildHosp — Oakland, California
- University Of California Irvine — Orange, California
- UC Davis Medical Center — Sacramento, California
- University of Connecticut — Farmington, Connecticut
- Yale University — New Haven, Connecticut
- Children's National Health Hospital — Washington D.C., District of Columbia
- Howard University — Washington D.C., District of Columbia
- Cornerstone Research Institute — Altamonte Springs, Florida
- University of Florida — Gainesville, Florida
- Foundation for Sickle Cell Disease Research — Hollywood, Florida
- University Of Miami — Miami, Florida
- Advanced Pharma CR — Miami, Florida
- Arnold Palmer Children's Hospital — Orlando, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Sonar Clinical Research — Atlanta, Georgia
- Children's Healthcare of Atlanta Investigational Medication Pharmacy — Atlanta, Georgia
- Center for Blood Disorders Augusta University — Augusta, Georgia
- iResearch Atlanta, LLC — Decatur, Georgia
- University of Illinois at Chicago — Chicago, Illinois
- Children's Hosp-New Orleans — New Orleans, Louisiana
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease
- Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — Birmingham, Alabama
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
- Acupressure in Patients With Sickle Cell Disease — Irvine, California
- Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina
Explore by condition: All Sickle Cell Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.